bicalutamid-bp 50 mg comprimate
sc balkan pharmaceuticals srl - bicalutamidum - comprimate - 50 mg
bicalutamide 150 mg comprimate filmate
hetero labs ltd - bicalutamidum - comprimate filmate - 150 mg
bicalutamide 50 mg comprimate filmate
hetero labs ltd - bicalutamidum - comprimate filmate - 50 mg
lojuxta
amryt pharmaceuticals dac - lomitapida - hipercolesterolemia - agenți de modificare a lipidelor - lojuxta este indicat ca adjuvant la o dieta de low‑fat şi alte lipid‑lowering cu muzica medicamentelor cu sau fără low density lipoprotein (ldl) afereză la pacienţii adulţi cu hipercolesterolemie homozigotă familială (hofh). confirmarea genetică a hofh ar trebui să fie obținute ori de câte ori este posibil. alte forme de primar hyperlipoproteinaemia și cauzele secundare de hipercolesterolemie (e. sindrom nefrotic, hipotiroidism) trebuie să fie excluse.
xtandi
astellas pharma europe b.v. - enzalutamide - prostate neoplasme - terapia endocrină - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
firmagon
ferring pharmaceuticals a/s - degarelix - prostate neoplasme - terapia endocrină - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
zoladex 3,6 mg
astrazeneca uk limited - goserelinum - implant - 3,6mg - hormoni si substante inrudite analogi de gonadorelina
zoladex la 10,8 mg
astrazeneca uk ltd. - goserelinum - implant - 10,8 mg - hormoni si substante inrudite analogi de gonadorelina
reseligo 3,6 mg
amw gmbh arzneimittelwerk warngau - germania - goserelinum - implant in seringa preumpluta - 3,6mg - hormoni si substante inrudite analogi de gonado relina
reseligo 10,8 mg
amw gmbh arzneimittelwerk warngau - germania - goserelinum - implant in seringa preumpluta - 10,8mg - hormoni si substante inrudite analogi de gonado relina